TABLE 2.

Univariable and multivariable baseline predictors of antibodies to infliximab (ATI) development

	Univariable			Multivariable
	OR	95% CI	P value	OR	95% CI	P value
Age <10 years	3.74	0.92–25.3	0.10	–	–	–
Starting dose <7.5 mg/kg	2.65	0.85–8.33	0.09	5.47	1.53–21.02	0.01
Baseline neutrophil CD64 activity ratio >6	3.95	1.25–13.03	0.02	6.23	1.80–23.54	0.005
Baseline albumin (g/dL)	0.64	0.26–1.51	0.32	–	–	–
Baseline C-reactive protein (mg/dL)	1.16	0.86–1.66	0.37	–	–	–
Baseline erythrocyte sedimentation rate (mm/h)	1.02	0.99–1.05	0.22	–	–	–
Week 0–14 exposure (AUC) goal, 79 348 μg h/mL	0.31	0.11–0.84	0.02	–	–	–

Abbreviations: AUC, area under concentration curve; CI, confidence interval; OR, odds ratio.